Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2003 1
2005 1
2007 1
2008 1
2021 2
2022 2
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections.
Jacobsson S, Golparian D, Oxelbark J, Wicha WW, da Costa RMA, Franceschi F, Brown D, Louie A, Gelone SP, Drusano G, Unemo M. Jacobsson S, et al. Among authors: oxelbark j. Front Pharmacol. 2022 Nov 14;13:1035841. doi: 10.3389/fphar.2022.1035841. eCollection 2022. Front Pharmacol. 2022. PMID: 36452226 Free PMC article.
Pharmacodynamic Evaluation of Zoliflodacin Treatment of Neisseria gonorrhoeae Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model.
Jacobsson S, Golparian D, Oxelbark J, Franceschi F, Brown D, Louie A, Drusano G, Unemo M. Jacobsson S, et al. Among authors: oxelbark j. Front Pharmacol. 2022 Apr 14;13:874176. doi: 10.3389/fphar.2022.874176. eCollection 2022. Front Pharmacol. 2022. PMID: 35496288 Free PMC article.
Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against Neisseria gonorrhoeae in a Dynamic Hollow Fiber Infection Model.
Jacobsson S, Golparian D, Oxelbark J, Alirol E, Franceschi F, Gustafsson TN, Brown D, Louie A, Drusano G, Unemo M. Jacobsson S, et al. Among authors: oxelbark j. Front Pharmacol. 2021 May 21;12:682135. doi: 10.3389/fphar.2021.682135. eCollection 2021. Front Pharmacol. 2021. PMID: 34093206 Free PMC article.
Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125-1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea.
Unemo M, Golparian D, Oxelbark J, Kong FYS, Brown D, Louie A, Drusano G, Jacobsson S. Unemo M, et al. Among authors: oxelbark j. J Antimicrob Chemother. 2024 May 2;79(5):1006-1013. doi: 10.1093/jac/dkae063. J Antimicrob Chemother. 2024. PMID: 38497988
Chromatographic comparison of bupivacaine imprinted polymers prepared in crushed monolith, microsphere, silica-based composite and capillary monolith formats.
Oxelbark J, Legido-Quigley C, Aureliano CS, Titirici MM, Schillinger E, Sellergren B, Courtois J, Irgum K, Dambies L, Cormack PA, Sherrington DC, De Lorenzi E. Oxelbark J, et al. J Chromatogr A. 2007 Aug 10;1160(1-2):215-26. doi: 10.1016/j.chroma.2007.05.057. Epub 2007 May 23. J Chromatogr A. 2007. PMID: 17559860
12 results